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Abstract
Background: People with psychosis have a reduced life expectancy of 10–20 years, largely due to cardiovascular
disease. This trial aimed to determine the effectiveness of a modular health promotion intervention (IMPaCT
Therapy) in improving health and reducing cardiovascular risk in psychosis.
Methods: A multicentre, two arm, parallel cluster RCT was conducted across five UK mental health NHS
trusts. Community care coordinators (CC) were randomly assigned to training and supervision in delivering
IMPaCT Therapy or treatment as usual (TAU) to current patients with psychosis (cluster). The primary outcome
was the physical and mental health subscales of the Short form-36 (SF-36) questionnaire.
Results: Of 104 care coordinators recruited, 52 (with 213 patients) were randomised to deliver IMPaCT therapy and 52
(with 193 patients) randomised to TAU. Of 406 patients, 318 (78%) and 301 (74%) attended 12- and 15-month follow-
up respectively. IMPaCT therapy showed no significant effect on the physical or mental health component SF-36 scores
versus TAU at 12 or 15 months. No effect was observed for cardiovascular risk indicators, except for HDL cholesterol,
which improved more with IMPACT therapy than TAU (Treatment effect (95% CI); 0.085 (0.007 to 0.16); p = 0.034). The
22% of patients who received >180 min of IMPACT Therapy in addition to usual care achieved a greater reduction in
waist circumference than did controls, which was clinically significant.
Conclusion: Training and supervising community care coordinators to use IMPaCT therapy in patients with psychosis is
insufficient to significantly improve physical or mental health quality of life. The search for effective, pragmatic interventions
deliverable in health care services continues.
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Background
There is a wealth of evidence demonstrating that people
with psychosis, including schizophrenia, schizoaffective
disorder and bipolar disorder, have considerably worse
physical health than the general population [1, 2]. Of
particular concern are the high rates of diabetes, meta-
bolic syndrome (MetS) and cardiovascular disease
(CVD) [2]. This increased CVD risk profile is the largest
risk factor for the reduction in life expectancy of be-
tween 10 and 20 years observed in people with psychosis
[3, 4]. Furthermore this mortality gap is widening [3, 4].
The underlying causes of the increase in CVD and
premature mortality are complex and multi-factorial.
Whilst genetic factors and shared pathophysiological
mechanisms contribute, unhealthy lifestyles including
high rates of smoking, alcohol use disorders, poor diet,
high levels of sedentary behaviour and low levels of
physical activity are modifiable factors [1, 2]. In the
general population, levels of CVD appear to have
plateaued, but they are increasing for people with
psychosis [5]. This may be in part because general
public health initiatives, such as smoking cessation
campaigns and calls to increase physical activity, do
not effectively reach this population [6].
Our recent [7] large UK prevalence study, conducted
as part of the baseline for this trial demonstrated that
nearly two-thirds of people with established psychosis
had MetS; similar to the 54.8% reported in the second
Australian national survey of psychosis [8] with ex-
tremely high levels of central obesity. A Spanish study,
using a different definition of MetS, found that patients
with schizophrenia treated with antipsychotics had simi-
lar rates of MetS to people 10 to 15 years older in the
general population [9, 10]. Additionally, 28% of the UK
sample had “hazardous drinking” (AUDIT score ≥ 8),
23% had a high saturated fat intake [11], and on average
participants spent over 8 h of their waking day being
sedentary [7]. Of additional concern, 62% (n = 268/432)
smoked tobacco, with a mean of 18 cigarettes per day,
comparable to the 66.1% reported in the Australian
study [7, 8].
A recent meta-analysis [12] of 17 randomised control
trials (RCT) demonstrated a modest positive influence of
lifestyle interventions on the prevention and reduction
of weight gain and cardiometabolic risk in people with
psychosis. Exercise [13] and health-mentor delivered nu-
tritional and exercise interventions [14] also display
promise. Whilst these results are encouraging, to date
the majority of such interventions targeting people with
psychosis have been ‘added on’ to standard care or focus
on individual risk factors such as weight or BMI. Such
interventions may exclude those patients not attending
community mental healthcare services regularly or with
difficulties in organisation or motivation. Nor do they
fully allow for the multiple health risks experienced by
this population. To date, few large-scale long-term RCTs
have attempted to improve health in its widest sense in
people with psychosis, with most concentrating on a sin-
gle target, usually weight, with interventions largely run
by therapists outside of the usual clinical team. Some
studies have co-located the work; for instance, Daumit
[15] et al. found that offering free exercise classes and
healthy meals in community rehabilitation centres suc-
cessfully reduced weight in people with psychosis, but
again these were separate from usual mental health care
and the intervention involved a high level of intense in-
put. Moreover, the recent In SHAPE study [16] in the
US relied upon attendance at a public fitness club, which
can prove a barrier for some people with psychosis with-
out adequate support. A well-designed large RCT in
Denmark, running in parallel with IMPaCT, evaluated
an intense intervention of add-on multifactorial lifestyle
coaching and additional care co-ordination delivered in
the patient’s usual healthcare setting but recently re-
ported that this did not reduce cardiovascular risk [17].
Moreover, like much of the other work to date it in-
volved significant additional input, which will have cost
implications. The evidence-base therefore is not yet suf-
ficient to plan services. There is a need for effective and
cost-effective ways to reduce cardiovascular risk in a way
that is accessible to all patients in community mental
health services.
We therefore used the emerging knowledge base to
design the content of a novel, manualised, modular
health promotion intervention (HPI) to manage physical
health and substance use disorders in people with psych-
osis – IMPaCT Therapy [18]. We chose an over-arching
primary outcome measure, quality of life, to reflect both
mental and physical health states, rather than focus on
one specific marker of cardiometabolic risk. We
hypothesised that the integration of IMPACT therapy
with usual care would be more effective than usual men-
tal health care in improving quality of life as measured
by the physical (PCS) and mental (MCS) component of
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the Short form (SF)-36 scale [19], at 12-months follow-
up in people with psychosis. We proposed that this
would be sustained 3 months after completion of the
formal intervention, at 15-months follow up. We also
hypothesised that the addition of IMPaCT therapy to
TAU would result in better cardiometabolic outcomes
and healthier lifestyle/substance use choices than in
those receiving TAU alone.
Methods
Development of the Health Promotion Intervention
(IMPaCT Therapy)
We developed a novel integrated health promotion
intervention (HPI), IMPaCT therapy, drawing on key
principles of two existing effective interventions for
physical health and substance use; the “Well-being Sup-
port Programme” [20] and “Managing Mental Health
and Drug Use” [21], adapted for use in routine clinical
care and implementation by the patient’s usual care co-
ordinator. In UK secondary care community mental
health services, care coordinators are the main point of
clinical contact and are from multiple professions; usu-
ally mental health nursing but also social work, psych-
ology or occupational therapy. The intervention aimed
to be pragmatic enough to be deliverable within the Na-
tional Health Service (NHS).
IMPaCT therapy was refined following a staged model
of behavioural therapies development [22–24]. The focus
and key principles were guided by current literature re-
garding effective physical health interventions in mental
health populations, which proposed integration of phys-
ical and mental health treatment, included Motivational
Interviewing and Cognitive Behavioural Therapy ap-
proaches, and addressed a broader range of physical
health and substance use targets [25–27], delivered over
9 months [28, 29].
IMPaCT therapy went through 3 stages of design and
analysis: (1) development of therapy and training, and
manual writing, incorporating consultation between ex-
perts in mental and physical health, substance use and
diabetes; (2) piloting, evaluation and refining of the train-
ing package with clinicians and (3) Delphi process to reach
consensus on the therapy model and manual. The Delphi
process comprised an initial consultation followed by 2
rounds of follow-up questionnaire feedback from (i)
expert therapist researchers (ii) clinician providers within
Community Mental Health Teams(CMHTs) and (iii)
psychosis service users.
Specifically, IMPACT Therapy [18] used motivational
interviewing (MI) techniques to address lifestyle choices,
with modules targeting the key areas of exercise, diet, to-
bacco smoking, alcohol use, cannabis use, other illegal
substances and diabetes (where applicable), plus integra-
tion of cognitive behaviour therapy (CBT) skills to
support behaviour change and mental health. To support
the intervention, we published in book form a manual
and a reference guide for clinicians and a handbook for
service users [18]. We developed a four-day training
programme for practitioners, encompassing skills and
knowledge on physical health, substance use, health pro-
motion, running groups, cognitive behavioural therapy
and motivational interviewing. This was well attended
and well received with an increase in mean self-rated
knowledge scores from pre to post training on all core
areas of training (physical health, substance use, running
groups and using motivational interviewing).
Study design and setting
We used a pragmatic multicentre, two arm, parallel clus-
ter RCT design, integrated within community mental
health teams (CMHTs) across five mental health NHS
trusts in South London, Kent, Sussex, Somerset and
Staffordshire, representing an urban to rural population.
The study was planned and implemented in concord-
ance with the Consolidated Standards of Reporting Tri-
als (CONSORT) cluster trial extension standards [30]
and details of method, measures, procedure, sample size
calculation are described in the published protocol [31].
Ethical approval was obtained from the joint South
London and Maudsley and the Institute of Psychiatry
NHS Ethics Committee (REC Ref no 09/HO80/41). Col-
leagues with lived experience, both service users and
carers, were involved throughout the research, from ap-
plying to funding to managing the steering group, to co-
authoring this paper.
Participants
Care co-ordinators in participating CMHTs who were
permanently employed and had a minimum of four
psychosis patients on their on their caseload who were
eligible to participate in the study. The participants eli-
gible for inclusion were aged between 18 and 65 years
with a diagnosis of a psychotic disorder (ICD 10 diagno-
sis F20–29, F31.2, F31.5). Patients were excluded if they
a) had a primary diagnosis of learning disability, b) had a
pre-existing physical health problem that would inde-
pendently impact on metabolic measures (as judged by
medical investigators), c) were currently pregnant or less
than 6 months post-partum or d) had a life threatening
or terminal medical condition. We did not recruit from
first episode psychosis services.
Study procedure
The study procedure is published and available with
open access [31], but will briefly be described. Recruit-
ment of participants occurred in two waves; first, eligible
community care coordinators were approached in a ran-
dom sequence and invited to participate. Once a care
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co-ordinator gave informed consent, the patients from
their caseload who met the inclusion criteria were likewise
approached in a random order and sequentially invited to
participate, until either 4 participants consented, or all eli-
gible patients had been approached. Once baseline assess-
ments were completed on all consenting patients in a care
co-ordinator’s caseload, that care coordinator was rando-
mised, stratified by borough (to allow for socio-economic
differences between boroughs) using randomisation
blocks of random sizes, to delivering IMPaCT Therapy or
TAU alone to their own current patients (cluster). Re-
searchers and the statistician remained blind to treatment
allocation. Recruitment started on 01/03/2010 and the
first date of randomization was 09.08.2010.
In the treatment arm, the intervention (IMPaCT Ther-
apy) was provided by each patient’s usual community
care coordinator who, within 3 months of randomisa-
tion, received the four-day IMPACT training course.
Participating care coordinators were offered fortnightly
supervision in IMPaCT Therapy throughout the subse-
quent 9-month intervention. Additionally, all care coor-
dinators were offered a one-hour training session in best
practice for physical health awareness to ensure more
standardised treatment as usual (TAU).
Outcome measures
Change in outcome was defined as difference from pre-
randomisation (baseline) and i) at completion of the su-
pervised intervention (12 months) and ii) 3 months after
the end of treatment (15 months). Time windows to col-
lect this data around the defined time points were estab-
lished (minus 6 weeks/plus 4 weeks at 12 months and
plus/minus 4 weeks for 15 month follow up). Data col-
lected outside these times were recorded but only used
for sensitivity analyses and not the main analysis.
Primary outcome
Primary outcomes were the physical and mental health
component scores of the SF-36 [19] at 12 and 15 months.
A range of socio-demographic data was collected in-
cluding age, sex, self-report ethnicity, marital status and
current medications. Full details of measures are in-
cluded in the protocol [31] In brief, secondary outcome
measures included:
Physical health measures: Fasting blood samples in-
cluding total, high (HDL) and low density lipoprotein
(LDL) cholesterol, triglycerides, glycated haemoglobin
(HBA1c) and C-reactive protein (CRP). Anthropometric
measurements (waist circumference, body mass index
(BMI), blood pressure) were also taken [31]. The Inter-
national Diabetes Federation (IDF) criteria for Metabolic
syndrome (MetS) were used to define abnormalities [32].
Substance use measures: Alcohol use was recorded
using the Alcohol Use Disorders Identification Test
(AUDIT) [33], tobacco use with the Nicotine Depend-
ence Questionnaire [34], while use of cannabis and other
illegal substances (opiates, methamphetamine, cocaine)
was recorded using the Time Line Follow Back [35].
Lifestyle measures: Dietary pattern and physical activity
were quantified according to the Dietary Instrument for
Nutrition Education (DINE, [11]) and the short form
International Physical Activity Questionnaire (IPAQ-SF,
[36]) respectively.
Mental Health status: Participants completed the Posi-
tive and Negative Syndrome Scale (PANSS [37]), Global
Assessment of Functioning (GAF) [38], SF-36 and Mont-
gomery Asberg Depression Rating Scales (MADRS, [39]).
Sample size
The power analyses were performed for the two sub-
scales measures, physical and mental health components
of SF-36 Quality of Life scale [19]. A sample size of 70
care coordinators each with an average of 4 patients (in-
flation factor 1.15 based on an assumed intraclass correl-
ation of 0.05) and thus 280 patients, after allowing for
20% loss of care coordinator and an additional 30% loss
of patients to follow up, was needed to detect a reduc-
tion of 5 points on both physical (d = 0.5) and mental
health scale (d = 0.42) with at least 80% power using an
alpha level of 0.05 and two-tailed assumptions.
Statistical analysis
The primary statistical analyses were based on the
intention to treatment principle and targeted at estimat-
ing the difference in the mean outcomes between partic-
ipants randomised to HPI and TAU at the two post-
treatment observation time points (12 and 15 months)
using mixed effects models. Bias due to missing follow-
up data was assessed by comparing baseline characteris-
tics of those with and without complete data. In the two
linear mixed effects models, physical and mental health
component scores, respectively, at 12 months and
15 months constitute the dependent variable. “Treat-
ment randomisation group”, “time (with two levels 12-
and 15- months post-randomization)”, the interaction
between “treatment group and time”, “centre”, and the
“baseline values of physical and mental health compo-
nent scores, respectively, are the fixed part of the
model”. An unstructured covariance pattern model was
used to model the dependency of the repeated observa-
tions of the same subject while care coordinator was
included as a random factor to account for the depend-
ency of the subjects within a cluster. Model assumptions
were assessed by visual inspection of the residuals. Stan-
dardised effect sizes (using pre-randomisation variability
for standardisation) are also reported.
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Sensitivity analyses
Because about 15% of the observations were collected out-
side the time window we repeated the analyses using all
available data as a sensitivity analyses. Demographic and
clinical baseline characteristics were similar for both arms
and we therefore did not perform any sensitivity analyses
with baseline covariates [40]. Nor did we pre-specify any
subgroup analyses to assess treatment effects to avoid in-
creasing false positive and false negative findings due to
inadequate power [41].
Handling of missing data
Models were rerun with predictors related to outcome
missingness included as further covariates in the model.
For the main outcomes, a second sensitivity analysis of
missing outcome data, using multiple imputations by
chained regression equations, was performed separately
for each treatment group, using all available clinical and
demographic scores.
Secondary outcomes
Secondary outcomes were analysed using the same
methods as for the primary outcome. However, for all
models the interaction between treatment group and time
was not significant and was removed from the final ana-
lyses. Treatment effects are therefore estimates for both
time points. Logistic mixed models were used for binary
outcomes (such as smoking) and Poisson mixed models
for count data (such as number of cigarettes per day).
Role of the funding source
The funding body were not involved in the design, run-
ning or reporting of the trial.
Results
In total, 104 care coordinators were randomised into the
IMPACT health promotion intervention (HPI) and con-
trol group (TAU). Overall, 406 patients from randomised
care coordinators were eligible and consented for the
trial. Fifty-two care coordinators (with 213 patients,
mean patients per care coordinator: 4.1, SD = 1.6, range
1–10) were randomized into HPI and 52 care coordina-
tors (with 193 patients, mean patients per care coordin-
ator 3.7, SD = 1.4, range 1–6) were randomised into
TAU (Fig. 1 Consort diagram). Three hundred eighteen
of the 406 patients (78.3%) attended the 12 months–fol-
low-up and 301 (74.1%) attended 15 months follow-up.
However, some of the patients who attended follow-up
assessments were not seen within the required time-
frame (10.5–13 months for 12 months and 14–16 for
15 months), so that the total sample size was reduced to
263 (64.8%) for 12 months (TAU: 132, HPI: 131) and
238 (58.6%) for 15 months (TAU: 114, HPI: 124). Three
hundred and fourteen patients (77.3%, HPI: 75.6%, TAU:
79.3%) were seen at least at one time point within the time
window and follow-up rates did not differ significantly be-
tween arms (12 months: chi2(1) = 1.81, p = 0.18, 15 months:
chi2(1) = 1.80, p = 0.18). The required sample size based on
the power analyses was achieved at both time points.
Pairwise comparison of baseline characteristics revealed
that subjects who did not attend at 12 months follow-up
were significantly younger (41.5 years (SD = 10.6)) than
patients who did attend (44.9 years (SD = 9.88), (t(404) =
1.77, p = 0.005) and tended to have smaller baseline waist
circumferences (103.6 cm (SD = 19.56) versus 107.6 cm
(SD = 17.43)). Non-attendance at 12 months follow-up dif-
fered between centres (p = 0.01). No other demographic
and clinical baseline characteristics differed significantly
between attenders and non-attenders.
There were no significant differences in baseline char-
acteristics between patients who attended within and
outside the time windows.
Demographic and clinical characteristics at baseline
are presented in Tables 1 and 3. Patients at baseline were
on average 45 years old (range 22 to 66), predominantly
male (55%) white (55%) and single (65%). Black patients
were the main ethnic minority group (34%). The mean
SF-36 Mental health score was 43.3 (range 9.6 to 67.7)
and the Physical health score was 48.0 (18.8 to 68.3).
Demographic and clinical baseline characteristics were
similar for both arms except for some small difference in
the relative number of patients per centre which was as-
sociated with small differences in the number of care co-
ordinator per arm per centre (note; one centre had only
one participating care co-ordinator).
Primary outcome analyses
The mixed effect model analyses revealed no significant
treatment effect for change in either Physical or Mental
health scores between TAU and IMPaCT at either 12 or
15 months (Fig. 2, Table 2). Estimated treatment effect
sizes were small (Physical health score, d = −0.17 at
12 months and −0.09 at 15 months, Mental health score,
d=: 0.03 at 12 months and −0.05 at 15 months). There
were no significant differences in effect between centres.
After removing the non-significant interactions between
treatment arm and time, patients in the treatment group
showed a non-significant decrease of 1.4 (95% CI: -3.2 to
0.41, p = 0.13, d = −0.12) in physical health scores and
0.13 (95% C.I -2.49 to 2.24), p = 0.92, d = −0.01) in men-
tal health scores compared to the patients in the control
group after adjusting for baseline differences.
Sensitivity analyses
Including data obtained outside the observation period
resulted only in minor changes and did not alter the
conclusion. Similarly, including age as a predictor of miss-
ingness and a multiple imputation analyses for missing data
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Fig. 1 Consort diagram
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resulted only in minor changes and did not alter the con-
clusion that there was no significant treatment effect at any
time point (Models with age (raw figures) included: physical
health score: d = −1.52 (95% CI -3.3 to 0.26, p = 0.094,
Mental health score d = −0.09 (95% C.I. -2.45 to 2.27), p =
0.94; Multiple imputation: Treatment effect Physical health
score, d = −0.78 (95% C.I.: -3.76 to 2.20), p = 0.61, mental
health score, d = −0.27 (95% C.I.: -3.82 to 0.27), p = 0.90; all
analyses without treatment x time interaction).
Secondary outcomes
Table 3 shows estimated treatment effects of the second-
ary clinical outcomes at 12 and 15 months follow-up.
The only significant difference in any of the secondary
outcomes at either 12 or 15 months was in HDL Choles-
terol, which improved more with IMPACT therapy than
in the TAU group (Treatment effect (95% CI); 0.085
(0.007 to 0.16); p = 0.034, Cohen’s d = 0.2). The other ef-
fect sizes (Cohen’s d) for continuous outcomes ranged
from −0.15 to 0.19. Twenty-eight patients (13.15%) in the
HPI group showed a serious adverse event (SAE) while 21
(10.88%) of the patients in TAU showed an SAE. This
difference is not significant (chi2(1) = 0.41, p = 0.52).
Care coordinators (CC) allocated to the HPI arm of
the trial saw their patients for an average of 8.44 (SD
5.3; range 0–25) sessions over the course of the trial.
These sessions lasted on average (50.7 min (SD 27.1). Of
this, a median of 20 min was dedicated to the HPI rather
Table 1 Demographic characteristics of participants at baseline for each trial arm and all patients combined
TAU (N = 193, 117
male)
HPI (N = 213, 117
male)
Total (N = 406, 234
male)
Mean (SD)
or No.
Range
or %
Mean (SD)
or No.
Range
or %
Mean (SD)
or No.
Range
or %
Age at baseline Years 44.65
(10.17),
22.95–
65.96
43.76
(10.09)
21.89–
65.94
44.18
(10.12)
21.89–
65.96
Education None 47 24.6 61 28.6 108 26.7
GSCE/O-Level/Level 1 or 2 NVQ 68 35.6 91 42.7 159 39.4
A-Level/Level 3/NVQ 33 17.3 33 15.5 66 16.3
Bachelor Degree/Graduate Certificate/Diploma or
post-graduate qualification
43 22.5 28 13.1 71 17.6
Total 191 100 213 100 404 100
Ethnicity White 100 52.1 122 57.8 222 55.1
(4 groups) Black 68 35.4 69 32.7 137 34.0
Asian 8 4.2 7 3.3 15 3.7
Mixed and other 16 8.3 13 6.2 29 7.2
Total 192 100 211 100 403 100
Relationship status Single 118 61.1 139 66.2 257 63.8
Married/co-habiting 29 15 27 12.9 56 13.9
Steady relationship 20 10.4 15 7.1 35 8.7
Divorced/Separated/Widowed 26 13.4 29 13.9 55 13.7
Total 193 100 210 100 403 100
Borough Croydon 33 17.1 25 11.7 58 14.3
Lambeth 23 11.9 21 9.9 44 10.8
Lewisham 34 17.6 50 23.5 84 20.7
Southwark 42 21.8 41 19.2 83 20.4
Greenwich 20 10.4 25 11.7 45 11.1
Bromley 9 4.7 10 4.7 19 4.7
Bexley 12 6.2 11 5.2 23 5.7
East Sussex 12 6.2 11 5.2 23 5.7
Somerset 8 4.1 9 4.2 17 4.2
South Staffordshire 0 0 10 4.7 10 2.5
Total 193 100 213 100 406 100
TAU treatment as usual, HPI IMPACT therapy (Health Promotion Intervention)
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than usual care. Minimum adherence to the intervention
protocol was defined as at least 6 sessions. In interpret-
ing the data, we later defined the minimum session dur-
ation as 30 min in addition to routine care; this was
delivered by 9 (17.3%) out of the 52 HPI care coordina-
tors to 19 of their patients. Forty-seven patients (22.0%),
under the care of 19 care coordinators (36.5%) in the
treatment group, either attended at least six 30-min ses-
sions of IMPaCT Therapy in addition to their usual con-
tact time or had the same therapy duration (180 min)
spread over more than 6 sessions. These patients had a
non-significant decrease of 2.45 (95% CI: -5.51 to 0.62,
d = −0.23, p = 0.12) in physical health scores and 0.84
(95% C.I -4.44 to 2.76), d = −0.02, p = 0.65) in mental
health scores compared to the patients in the control
group over the 12 months, after adjusting for baseline
differences. They had a significantly greater reduction in
waist circumference over 12 months than did controls
(−4.20 cm (95% C.I. -7.18 to – 1.23), p = 0.006). All
other assessed variables remained non-significant, but
only continuous outcomes could be assessed due to the
smaller sample size.
Discussion
Statement of principal findings
The current study, the largest pragmatic trial of a MI/
CBT HPI intervention in the UK, delivered by care coor-
dinators to their own patients with psychosis and inte-
grated into secondary care practice, found the addition
of IMPaCT therapy had no significant effect on our
44
45
46
47
48
49
50
51
52
Baseline 12 mo 15 mo
TAU HPI
Physical Health Component Score
38
40
42
44
46
48
50
Baseline 12 mo 15 mo
TAU HPI
Mental Health Component Score
Fig. 2 Mean Physical health and mental health component score (95% Confidence interval) at baseline, 12 and 15 months follow-up for Treatment as
usual (TAU) and Health intervention programme group (HPI)
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primary outcomes of PCS and MCS quality of life
scores. In addition, there was little evidence that IMPaCT
therapy delivered by CCs improved cardiovascular risk in-
dicators, substance use or mental health measures com-
pared to TAU alone. The only advantage observed with
IMPaCT therapy over TAU at the intention to treat level
was in the relatively small effect on HDL cholesterol,
which must be interpreted with caution, in the context of
multiple testing (see Table 3). Higher HDL levels are
linked to cardiovascular health and respond to dietary
change and exercise.
Strengths of the study
This is the first RCT investigating an integrated health
promotion intervention designed to be used in routine
clinical care and implemented by the patient’s usual care
coordinator. The main strength of this trial is that it was
a pragmatic study set in the NHS, designed to be as rep-
resentative as possible. The NHS delivers the bulk of
healthcare to people with psychosis, largely in secondary
care, although if the course of illness is stable, people are
discharged to primary care. Community secondary care
treatment is led by care co-ordinators based in Commu-
nity Mental Health Teams (CMHTs) who see their pa-
tients in various settings; it was they who were invited to
take part in the trial and, if randomised to the treatment
arm, deliver the intervention. The HPI was thus access-
ible to the greatest possible proportion of people with
psychosis receiving secondary care, many of whom may
not wish, or may be too unwell to attend add-on or
group interventions. Thus it attempted to meet the
needs of this very hard-to-reach group with high rates of
cardiometabolic disease [7] by enhancing routine care.
The study recruited to target from a diverse multi-
ethnic sample of people with psychosis and had good
follow-up rates. There was no difference in dropout
between the active and control arms of the study, al-
though those who did not attend at 12 months
follow-up were younger. To limit multiple testing and
due to the small numbers in some sub-categories we
did not do sub-analyses of outcomes by ethnicity, age
groups or sex.
The relationship between borough and non-attendance
at 12 months follow-up is likely to be multifactorial.
This study attempted to influence lifestyle choices and
substance use, which affect both physical and mental
health. To date, few large-scale long-term RCTs have
attempted to improve health in its widest sense in
people with psychosis, with most concentrating on a sin-
gle target, usually weight, and interventions largely run
by therapists outside of the usual clinical team. Even
where the work has been co-located, they have been sep-
arate to usual care [15, 17]. Therefore, our integrated
personalised approach, conducted by the core mental
health clinician adapting to the patient’s individual
needs, attempted to address some of these concerns by
maximising representativeness of the population studied
and avoiding a piecemeal approach to behavioural
change. Further, our choice of the SF-36 PCS and MCS
scores as primary outcome measure reflected our hy-
pothesis that the lifestyle interventions would lead to a
general and perceptible improvement in both mental
and physical health. Our study, like the recent Change
RCT in Denmark [17], demonstrates the challenges of
reducing cardiovascular risk among those with estab-
lished psychosis.
Table 2 Results of the mixed effect linear model for main outcomes (physical and mental health score) with treatment arm at
12 months or 15 months
SF-36 Physical Health Score SF-36 Mental Health Score
Variable Coefficient (95% CI) z P Coefficient (95% C.I.) z p
Arm (HPI = 1) −1.77 (−3.88 to 0.34) −1.65 0.10 0.37 (−2.41 to 3.15) 0.26 0.79
Time (15 mo = 1) −0.15 (−1.73 to 1.44) −0.18 0.86 0.22 (−1.75 to 2.18) 0.22 0.83
Arm x Time 0.77 (−1.49 to 3.03) 0.67 0.51 −1.05 (−4.15 to 2.04) −0.67 0.51
Borough Chi2(9) = 8.37, p = 0.50 chi2(9) = 8.82, p = 0.45
Pairwise comparison Coefficient [95% CI] z P z P
12 mo: HPI vs TAU −1.77 (−3.88 to 0.34) −1.65 0.10 0.37 (−2.41 to 3.15) 0.26 0.79
15 mo: HPI vs TAU −1.00 (−3.15 to 1.14) −0.92 0.36 −0.68 (−3.56 to 2.19) −0.47 0.64
Group HPI: 15 mo vs 12 mo −0.15 (−1.73 to 1.44) −0.18 0.86 0.22 (−1.75 to 2.18) 0.22 0.83
Group TAU: 15 mo vs 12 mo 0.62 (−1 to 2.25) 0.75 0.45 −0.84 (−3.24 to 1.56) −0.68 0.49
Random effect care coordinator 1.06 (0.07 to 15.29) 2.17 (0.72 to 6.56)
Results of the mixed effect linear model for main outcomes (physical and mental health score) with treatment arm, time (12 months or 15 months), the interaction
between treatment arm and time, borough and baseline values of outcome. Pairwise comparisons show treatment effect estimates at 12 and 15 months and changes
from 12 to 15 months within each treatment arm. Care coordinator was included as a random factor to account for the dependency of observations with care coordinator.
The dependency of repeated observations within individuals was modelled by estimating the variance–covariance structure of the residuals
TAU treatment as usual, HPI IMPACT therapy (Health Promotion Intervention)
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Limitations of the study
There are a number of contextual factors that may have
influenced the outcome of the trial. First, this study was
funded before the promotion of improved physical
health and lifestyle choices among people with psychosis
was rising on the national and local NHS agenda. Since
that time in the UK alone, the ‘parity of esteem’ move-
ment to improve physical healthcare for people with
psychosis was successfully launched by the Royal College
of Psychiatrists, NICE published guidance on physical
health and the Quality and Outcomes Framework
(QOF) offered payment to GPs to monitor and advise on
physical health outcomes and lifestyle choices (e.g.
encouraging patients to stop smoking). It is likely that
participants in both treatment arms benefited from the
concerted efforts to improve the very outcomes we were
targeting within the study, although we did not
demonstrate a significant improvement in either arm
over the time frame of the study. Secondly, multiple re-
organisations among the participating hospital trusts af-
fected continuity of care. Staff turnover was slightly
greater in the treatment than control arms, although this
was not statistically different. In this context however, it
is interesting to note that where patients remained with
the same trained care coordinator throughout the trial,
there were indications that the intervention may result
in significantly lower cholesterol levels and more exer-
cise in the treatment arm than in controls. Thirdly, given
the integration with routine care, it was not possible to
control for conditions such as minutes per session. Des-
pite pilot development work and regular supervision be-
ing offered by research therapists, care co-ordinators
struggled to deliver 6 or more sessions of 30 min each of
the HPI in addition to routine care, with HPI sessions
lasting a median of 20 min. This highlights the recog-
nised challenges for care co-ordinators delivering tar-
geted psychosocial interventions to people with
psychosis in a busy secondary care environment. The
proportion of care co-ordinators who delivered the mini-
mum dose (17–36% dependent on the measure taken),
was in keeping with Harding et al. (under review [42])
who found that only 25% of care co-ordinators delivered a
brief CBT-based therapy despite adequate training and
supervision, compared to 62% of assistants without case
management responsibilities. This is also consistent with
other studies that have found that care co-ordinators
struggle to implement therapy alongside case manage-
ment [43, 44]. Where participants received the interven-
tion of at least 180 min in addition to routine care, the
significantly greater reduction in waist circumference than
in controls was of a clinically significant degree, suggesting
a dose effect once a minimum therapy time was delivered.
A further consideration is that our modular interven-
tions were broad and participants self-selected the target
behaviours to be focused on. It is possible that more
structured interventions targeted at specific health be-
haviours, such as those described elsewhere [15, 16, 45]
may be better placed to demonstrate statistically signifi-
cant improvement in defined aspects of the physical
health of this population. However, for the purposes
of routine care, a more long term, sustainable and in-
tegrated approach to global health behaviours is ur-
gently required.
Clinical and service implications
This is the first trial to address the question of whether
a health promotion intervention delivered by the core
mental health clinician as part of enhanced routine care
can achieve greater clinically significant health gains in
comparison to treatment as usual. The answer is that
this integrated approach did not appear to match the
modest health gains (usually measured by weight loss)
seen by adding group interventions to usual care – al-
though it would be of interest to compare representa-
tiveness of samples between this integrated (and thus
very accessible) approach and add-on interventions. Nor
was additional time for the intervention regularly deliv-
ered when rolled out across community mental health
teams. Thus the message to service planners is clear and
important – by itself focussed training and supervision
provision for front-line mental health workers does not
appear to be enough to change therapeutic practice
sufficiently to reverse cardiometabolic risk indicators
in their patients with established psychosis. However
our data suggests that continuity of care and pro-
tected time to deliver HPI work may well enhance
outcomes, an important practical point in today’s rap-
idly evolving health services.
A recent qualitative review of reviews [46] considering
non pharmacological interventions seeking to reduce
cardiometabolic risk concluded that interventions with
multiple components, personalized, with more frequent
face-to-face contact, and professionally trained treat-
ment providers are associated with better outcomes.
Given that our trial showed little effect at the intention
to treat level of training and offering supervision to
CMHT staff in delivering a HPI, it may be that widening
mental health teams to include specialists in exercise
and nutrition is necessary, as in the Keeping the Body in
Mind preventative programme in Sydney [47]. This will
have cost implications for service providers and thus
may introduce further barriers to accessing care, pend-
ing evaluation of the cost-effectiveness of such models.
Our results strongly support the notion that prevention
of emergence of cardiometabolic risk factors in early
psychosis is key, as reversing these in established illness
is extremely difficult [17]. Of note, only people with
established illness were included in our study.
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Focussing on reducing BMI and waist circumference is
notoriously challenging [46]. Future multicomponent in-
terventions might wish to consider cardiorespiratory fit-
ness (the ability of the circulatory and respiratory
systems to supply oxygen to working muscles during
sustained physical activity) as the primary outcome,
since there is mounting evidence that ‘fitness’ is also an
important predictor of mortality [48].
Conclusions
The current paper is the first randomised control trial in-
vestigating a health promotion intervention designed to be
used in routine clinical care and implemented by the pa-
tient’s usual care coordinator. Our study found that training
and supervising care co-ordinators to work with their own
patients with psychosis to change lifestyle choices is not in
itself sufficient to effect clinically or statistically significant
improvement in quality of life or overall cardiovascular risk
in people with established psychosis, although there was an
effect on waist circumference when the minimum dosage
was delivered. Given the need to reduce the life expectancy
gap between people with psychosis and the general
population, the search across health systems for more
effective, deliverable, affordable and sustainable interven-
tions remains a priority.
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